Five Alarm Bio (FAB), a drug discovery firm targeted on novel approaches to anti-aging, introduced right now it has accomplished a seed funding spherical, elevating over £500K GBP to additional allow its pioneering analysis. Investors taking part within the spherical embrace Cambridge Angels, Meltwind, o2h Ventures, and SyndicateRoom, in addition to different Angel traders, with assist from KPMG Acceleris. This funding follows a £360K Biomedical Catalyst grant from Innovate UK, awarded to FAB early final 12 months to develop its know-how as a therapy for continual wounds.
Based on breakthrough advances in understanding of how age-associated chemical harm accumulates in cells and tissues, FAB is growing an progressive small molecule method aimed toward boosting our defences as we age, to finally lengthen the wholesome lifespan of our our bodies. Age-related illnesses comparable to arthritis, sarcopenia and Alzheimer’s Disease are among the many main causes of incapacity and mortality throughout the developed world, and a significant burden on well being funding. Globally, the anti-aging therapeutics market is predicted to succeed in $2.01 billion by 20301.
This funding will drive additional analysis into FAB’s proprietary method, testing new compounds for his or her means to increase the wholesome lifespan of cells in vitro and enhance their operate in disease-relevant fashions. By concentrating on an unexplored mechanism of getting old, these compounds have the potential to delay or forestall the onset of a broad vary of age-related illnesses.
Dr Janette Thomas, CEO, Five Alarm Bio, stated: “Whilst life expectancy has elevated over latest years, our wholesome lifespan has not stored up. Anti-aging science subsequently has big worth. Here at FAB our proprietary method goals to beat this elementary problem to human well being as we work to find and develop new medicine for age-associated illnesses.
We wish to thank the traders in our seed funding spherical for his or her assist, and for his or her confidence in our workforce and the potential of our method.”
Sunil Shah, Co-founder, Five Alarm Bio, and CEO, o2h Ventures, commented: “FAB is at the forefront of the rapidly growing anti-aging therapeutics industry, with the potential to deliver new drugs that extend our healthy lifespan. We are delighted to have made this investment alongside Meltwind, Cambridge Angels, and SyndicateRoom. The combination of the scientific depth of our CSO, William Bains, alongside the practical execution skills of the CEO, Janette Thomas, provides a great team to discover and develop new drugs for age-associated diseases.”
Founded in 2016 by three extremely skilled entrepreneurs, FAB is at the moment based mostly in purpose-built lab amenities on the world-renowned Babraham Research Campus, Cambridge.
For extra info, please go to: http://www.fivealarmbio.com/.
- Press Release: Global Anti-aging Therapeutics Market price $ 2.01 Billion by 2030 – Exclusive Report by Insight Analytics (2 September 2022)